Skip to search formSkip to main contentSkip to account menu

tecemotide

Known as: Emepepimut-S, Glycine, L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-L-alanyl-L-histidylglycyl-L-valyl-L-threonyl-L-seryl-L-alanyl-L-prolyl-L-alpha-aspartyl-L-threonyl-L-arginyl-L-prolyl-L-alanyl-L-prolylglycyl-L-seryl-L-threonyl-L-alanyl-L-prolyl-L-prolyl-N6-(1-oxohexadecyl)-L-lysyl- 
A liposome-encapsulated peptide vaccine consisting of a synthetic peptide derived from the mucin 1 (MUC-1) antigen with potential antineoplastic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: Immune-based therapeutic strategies represent a promising approach in early and advanced breast cancer treatment… 
2016
2016
Locally-advanced non-small cell lung cancer (LA-NSCLC) is optimally treated with definitive chemoradiation or surgery in… 
2014
2014
Incorporating an effective and tolerable immunotherapeutic as part of maintenance therapy for unresectable stage III non-small… 
2014
2014
TPS7608 Background: Tecemotide is an antigen-specific cancer immunotherapy targeting the mucinous glycoprotein MUC1, which is… 
2013
2013
The results of a recently completed Phase III clinical trial suggest that concurrent chemoradiotherapy followed by tecemotide… 
2013
2013
• The program will build upon the data from START* trial and explore potential in patients with Stage III NSCLC who have… 
2000
2000
Regioselective functionalization of 2,4,5,6-tetrachloro-1, 3-dicyanobenzene (TCDCB) by nucleophilic substitution of the chlorine… 
1983
1983
Indirect evidence suggests that immunoglobulin A1 (IgA1) proteases may be factors in the pathogenesis of certain infectious… 
Highly Cited
1982
Highly Cited
1982
Haemophilus influenzae is one of five bacterial species known to produce IgA proteases, enzymes that specifically cleave the…